Andrea Loehr

Medicine · Health Sciences

17h-index2.4kcitations125works2.32yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Prostate Cancer Treatment and Research(65), PARP inhibition in cancer therapy(64), Cancer Genomics and Diagnostics(53), Genetic factors in colorectal cancer(26), DNA Repair Mechanisms(12)

Publications125 total

AI Evaluation Practices Consensus
Open Science Framework·2025Open Access
Supplementary Data 1 from Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP Inhibitors
2024Open Access
Supplementary Table S3 from Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP Inhibitors
2024Open Access
Supplementary Table S2 from Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP Inhibitors
2024Open Access
Data from Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP Inhibitors
2024Open Access
Supplementary Table S1 from Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP Inhibitors
2024Open Access
Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP Inhibitors
Clinical Cancer Research·2024· 16 citedOpen Access
Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study
European Urology·2023· 79 citedOpen Access
Suppl Fig S2C from Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study
2023Open Access
Table S3 from Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms
2023Open Access
Data from Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study
2023Open Access
Data from Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study
2023Open Access
Supplementary Figures from Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study
2023Open Access
Supplementary Data from Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study
2023Open Access
Suppl Fig S2C from Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study
2023Open Access
Table S4 from Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms
2023Open Access
Figure S6 from Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms
2023Open Access
Data from Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms
2023Open Access
Suppl Fig S2B from Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study
2023Open Access
Figure S11 from Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms
2023Open Access
page 1 of 7Next →

Frequent Co-authors

Wassim Abida(21), Andrew D. Simmons(21), Simon P. Watkins(19), Simon Chowdhury(19), Charles J. Ryan(16), Ray McDermott(14), Alan H. Bryce(13), Karim Fizazi(13), Jeremy Shapiro(12), Brieuc Sautois(12), Josep M. Piulats(12), Darrin Despain(12), Tony Golsorkhi(12), Nicholas J. Vogelzang(11), Akash Patnaik(10), Jingsong Zhang(10), Éric Voog(8), Laurence E. Krieger(8), Melanie Dowson(8), David Campbell(7)